A balanced guide for patients and clinicians

• Chronic pulmonary aspergillosis (CPA)

• Allergic bronchopulmonary aspergillosis (ABPA) (selected or refractory cases)

• Invasive aspergillosis

• Patients intolerant of itraconazole or voriconazole

• Antifungal prophylaxis in high-risk immunocompromised patients

It is generally well tolerated and often used when other azoles cause side effects.

---

1️⃣ What Posaconazole Does

Like other azoles, posaconazole blocks fungal ergosterol synthesis (CYP51 inhibition), preventing fungal growth.

It:

• Suppresses Aspergillus replication

• Reduces fungal burden

• Helps stabilise lung disease in CPA

• Can reduce steroid need in some ABPA cases

It works gradually over weeks.

---

2️⃣ How Long Is Treatment?

In CPA

• Often 6–12 months or longer

• Sometimes long-term suppressive therapy

• Used if other azoles are ineffective or not tolerated

In ABPA

• Used in refractory or steroid-dependent disease

In prophylaxis

• Duration depends on immune suppression status

As with other azoles, premature discontinuation may lead to relapse.

---

3️⃣ Formulations Matter

Posaconazole comes in:

• Delayed-release tablets

• Oral suspension

• Intravenous formulation

Tablets (preferred)

• Good, reliable absorption

• Less affected by food

• More predictable levels

Oral suspension

• Absorption highly dependent on food (especially fatty meals)

• Greater variability

In most CPA practice, tablets are preferred.

---

4️⃣ Why Blood Level Monitoring Is Still Important

Posaconazole has more predictable pharmacokinetics than itraconazole or voriconazole, but monitoring is still recommended.

Reasons:

• Interpatient variability

• Drug interactions

• Severe infection requires adequate exposure

• Toxicity avoidance

---

If Levels Are Too Low

• Inadequate fungal suppression

• Ongoing disease activity

• Risk of resistance

---

If Levels Are Too High

• Liver abnormalities

• Gastrointestinal symptoms

• Rare cardiac effects

---

Typical Target (Trough)

• 1 mg/L for treatment

• 0.7 mg/L often sufficient for prophylaxis

(Laboratory guidance varies.)

Levels are typically checked:

• After 5–7 days

• After dose adjustments

• If response is suboptimal

• If toxicity suspected

---

5️⃣ Common Side Effects (Usually Mild)

• Nausea

• Diarrhoea

• Abdominal discomfort

• Headache

These are often less troublesome than with voriconazole.

---

6️⃣ Less Common but Important Effects

Liver Abnormalities

Routine monitoring required.

Most are mild and reversible.

---

QT Interval Prolongation

Posaconazole can prolong QT interval.

Caution in patients with:

• Known arrhythmias

• Electrolyte imbalance

• Other QT-prolonging drugs

ECG monitoring may be appropriate in higher-risk individuals.

---

Hypertension & Mineralocorticoid Effect (Rare)

High levels can rarely cause:

• Elevated blood pressure

• Low potassium

More common with long-term or high exposure.

---

Neuropathy

Much less commonly reported than with other azoles, but peripheral symptoms should still be assessed carefully if they occur.

---

7️⃣ Food & Drug Advice

• Tablets: can be taken with or without food (follow prescribing guidance)

• Suspension: take with food (preferably fatty meal)

Avoid:

• Grapefruit

• St John’s Wort

Posaconazole inhibits CYP3A4 and interacts with:

• Statins

• Certain immunosuppressants

• Some anticoagulants

Medication review is essential.

---

8️⃣ Comparison Snapshot

---

Balanced Summary for Patients

Posaconazole is a newer azole that is often well tolerated and provides reliable antifungal coverage. Blood tests help ensure the level is effective and safe. Most patients complete treatment without major difficulties.

---

Clinician Checklist

• Confirm formulation (tablet preferred in CPA)

• Baseline LFTs

• Review ECG if cardiac risk present

• Check electrolytes (especially potassium)

• Arrange trough level after initiation

• Review full medication list